Shaping Genomic Science across a Quarter Century through Tools, Trends, and Translational Breakthroughs

Smaranya Singha Roy, Anirban Mukherjee
Department of Pharmacy
Guru Nanak Institute of Pharmaceutical Science and Technology, 157/F Nilgunj Road, Panihati, Kolkata – 700114, West Bengal, India, AM Educare Biotech Solutions Pvt. Ltd., Kolkata India
singharoysmaranya@gmail.com, anirban.microbio@gurudas.education

***Abstract*—The opening year of the twenty-first century constitutes a watershed moment in the historical evolution of genomics, marking a shift from an exclusive, resource-intensive enterprise to a globally distributed, high-resolution discipline. This review summarises the main technological and conceptual developments that have been realised since the year 2000 up until 2025 and evaluates their implications on basic research, clinical translation and cross-national cooperation. Eponymous triumphs involve the achievement of the Human Genome Project and consequent definition of genome regulatory rootlessness, emergence of sequencing that is next generation, and occurrence of the high accuracy of world rudiments instruments such as the CRISPR Cas methods. In the same time, the advent of single-cell and spatial multi-omics has generated unmatched comprehension of cellular heterogeneity and tissue organization, while artificial intelligence has markedly expedited protein structure modeling, variant interpretation, and drug discovery. Several consortia, including those focused on large-scale coverage (e.g., GenomeAsia 100K and the Earth BioGenome Project), are broadening the coverage of reference genomes and their accessibility, and new ethical, legal, and policy issues are emerging to do so. Collectively, these developments have reconfigured discovery pathways, fostered precision medicine, and elevated the societal relevance of genomics. In the future, multimodal dataset integration using analytics powered by AI is expected to bring measurable gains to health, drive environmental stewardship and directional biological exploration.**

***Index Terms*—genomics, genetics, single-cell, long-read sequencing, multi-omics, precision medicine.**

I. Introduction

The initial quarter of the 21st century has seen genetics and genomics transform from a resource-intensive, large-scale project into a globally accessible, high-resolution discipline that now uncovers much of medicine and modern biology. The completion of the Human Genome Project (HGP) accelerated downstream innovation in sequencing technologies and advanced data-sharing frameworks, catalyzing the transformation from single-gene studies to a systemic-level approach [1,2].

Concurrently, the toolkit of molecular biology expanded to a significant level. The introduction of huge parallel sequencing platforms modified the way whole-exome and whole-genome analysis was done, along with programmable genome editing systems like CRISPR-Cas, which transformed experimental genetics and opened different therapeutic directions [3]. Advancements in spatial

omics and single-cell genomics have revealed cellular heterogeneity and in situ organisation that bulk assays cannot capture, which promotes the formation of large-scale reference efforts. At the same time, Artificial Intelligence (AI) and deep learning have allowed step changes in predicting protein structure and large-scale data integration [4-6].

Technical innovation in the last 20 years has focused on genomics (especially sequencing and genome editing), and has been accompanied by consortium-scale projects, which together have increased the scale and representativeness of data. Simultaneously, the moral and policy environment has changed, and the issues of consent, fairness, and control have been discussed. Despite these advancements, there are still some hurdles remaining, which include a lack of diversity in patients, constraints on model interpretability, generalizability, and clinical translation. This review is therefore a synthesis of the key technological and conceptual advancements of the last 25 years (2000-2025) and the effects they have on discovery science, clinical translation, and international cooperation [7,8]. A concise timeline of major milestones is presented in Figure 1, followed by the main text, which proceeds through enabling technologies (sequencing, editing), computational integration (AI, multi-omics), population-scale resources, single-cell and spatial genomics, clinical applications, ELSI considerations, and realistic future directions grounded in active consortia and technological trajectories.



Figure 1: Timeline of key breakthroughs that occurred in genetics and genomics from 2000-2025, highlighting major technological, conceptual, and collaborative advances.

II. HGP and Rise of Genomics

Launched in 1990, the Human Genome Project (HGP) was completed in 2003, following the submission of its first draft in 2000. The completion of the project marked a remarkable landmark in

the fields of genomics and modern biology. This ground breaking initiative, led by the U.S National Institute of Health (NIH) and the Department of Energy (DOE), along with the collaborations of scientists across the globe, the scientists decoded over 3 billion base pairs of the human genome and revealed an insight stating that human contains fewer protein coding genes (roughly around 20,000-25,000) than originally predicted [9, 10]. These genes make up for less than 2% of the total genome, while the rest comprises the non-coding regions whose functions were not known back then. Following this remarkable discovery, the focus shifted from gene count to regulatory complexity, alternative splicing. Later, it was predicted that the non-coding regions may play a critical role in gene regulation and gene architecture. The HGP accelerated the innovations in different sequencing technologies, collaborative sciences, and data sharing technologies. HGP's foundational work provided a skeleton for interpreting functional and comparative genomics, disease gene mapping, which led to taking global initiatives like the ENCODE project and the 1000 Genome project [11-13]. Simultaneously, various foundational databases were developed, like Ensembl and the UCSC genome browser, which made genomic data more accessible for researchers worldwide. In the progressive years post-HGP, the world experienced a technological surge with the introduction of Next Generation Sequencing (NGS), which significantly reduced the cost and time required for whole genome analysis [14]. This emergence remodeled the background of biomedical research from expensive, large-scale, multi-institutional projects to regular operations in individual labs.

The successful completion of HGP was way more than just delivering a sequence. It re-explained the goals, tools, and possibilities in genomics science. It significantly marked a distinct change from gene gene-centric framework of classical genetics to a broader version of post-genomic biology, which led to the emergence of single-cell, multi-omics, and personalized medicine.

III. Next-Generation Sequencing and the Genomic Revolution

Following the completion of the Human Genome Project (HGP), DNA sequencing technologies underwent a dramatic evolution that transformed the formerly cumbersome and financially intensive practice into a high-throughput, scalable workflow. Although Sanger sequencing had revolutionised DNA characterisation, the rise of next-generation sequencing (NGS) in the mid-2000s produced marked improvements in terms of throughput [15], analysis speed, and cost efficiency. Various parallel sequencing platforms allowed this, with challenges that involved significant reduction in cost at a fraction of the cost of older machines, the main contenders being; Illumina, Roche 454 and Life Technologies SOLiD.

Sequencing efficiency at the rate it kept increasing, the whole-exome and whole-genome sequencing finally became available to individual labs all around the world. Such accessibility catalysed transformations in cancer genomics, population genetics, and the detection of rare diseases. This

gave rise to release of the exploding volumes of genetic information following the advent of NGS, necessitated by a need to look forward to concomitant advancements in bioinformatics, storage and techniques of interpreting genomic variations [16]. Subsequently, third-generation or long-read platforms such as Pacific Biosciences (PacBio) and Oxford Nanopore Technologies (ONT) emerged to address limitations inherent to NGS, including difficulties in resolving structural modifications, complex haplotypes, and repetitive sequences [17]. The systems have the ability to produce read lengths reaching into the tens of kilobases by single molecule methods in real time, giving researchers a broader picture of epigenomic variation and structural changes [18].

In sum, successive technological advances have propelled high-profile initiatives such as the Telomere-to-Telomere Consortium, stimulated novel areas of inquiry such as single-cell and spatial genomics, and enhanced the accuracy, speed, and affordability of genome sequencing—including the routine integration of long-read and short-read data in both clinical diagnostic and research settings.

IV. CRISPR and Genome Editing Technologies

One of the most transformative technologies in the era of 21st century was the advent of genome editing. This enabled minute amendments in the DNA sequence for diverse therapeutic applications and functional studies. Traditional genome editing platforms included Zinc Finger Nucleases (ZFNs) and Transcription Activator – Like Effector Nucleases (TALENs), which offered limited site-specific alteration capabilities, but the major drawback that restricted them from being widely used was the design complexity and limited scalability [19,20].

The discovery and acclimatization of the CRISPR-Cas9, a bacterial immune system, came as a breakthrough in the field of gene editing [21]. This system made the researchers gain the ability to precisely target and alter any DNA sequence using a programmable, RNA-guided system called Cas9 [22-24]. The discovery changed the structure of genome editing by making it easier, highly specific, and way more efficient. This technology has been applied to a range of different arenas, like as functional genomics, model organism development, synthetic biology, and human gene therapy. Except for Cas9 editing, newer platforms emerged like base editing, prime editing, and epigenome editing, which extended the functional range of CRISPR tools. The base editing parameters offer single-nucleotide precision in DNA editing without breaking its double strand, while prime editing offers programmable rewriting of DNA with fewer unintended effects [25]. Different epigenetic editing tools, like using dCas9 fused to p300 or KRAB, modify gene expression by changing the histone modifications and DNA methylation patterns without disturbing the fundamental DNA sequence. Genome editing has shown various therapeutic potentials with greater promises [26]. Satisfactory results have been found from the CRISPR-based therapies for sickle cell diseases and

β-thalassemia in the clinical trials, and ongoing research is still going on for various targeted diseases, ranging from inherited retinal disorders to cancer and viral infections. Even after various advancements, various technical barriers remain to clinical adoption, such as delivery mechanisms, off-target effects, unexpected immune responses, and ethical concerns in germline editing [26].

Altogether, the emergence of genome editing along with the tools has significantly redefined the pattern of studying genes and treating diseases. These tools have moved the research pattern from basic to advanced in clinical applications, specifically in arenas of altering disease-causing mutations. The continuous evolution of these studies, till today, is expected to treat a wider range of diseases with more precision and effectiveness.

V. CRISPR and Genome Editing Technologies

One of the most transformative technologies in the era of 21st century was the advent of genome editing. This enabled minute amendments in the DNA sequence for diverse therapeutic applications and functional studies. Traditional genome editing platforms included Zinc Finger Nucleases (ZFNs) and Transcription Activator – Like Effector Nucleases (TALENs), which offered limited site-specific alteration capabilities, but the major drawback that restricted them from being widely used was the design complexity and limited scalability [19,20].

The discovery and acclimatization of the CRISPR-Cas9, a bacterial immune system, came as a breakthrough in the field of gene editing [21]. This system made the researchers gain the ability to precisely target and alter any DNA sequence using a programmable, RNA-guided system called Cas9 [22-24]. The discovery changed the structure of genome editing by making it easier, highly specific, and way more efficient. This technology has been applied to a range of different arenas, like as functional genomics, model organism development, synthetic biology, and human gene therapy. Except for Cas9 editing, newer platforms emerged like base editing, prime editing, and epigenome editing, which extended the functional range of CRISPR tools. The base editing parameters offer single-nucleotide precision in DNA editing without breaking its double strand, while prime editing offers programmable rewriting of DNA with fewer unintended effects [25]. Different epigenetic editing tools, like using dCas9 fused to p300 or KRAB, modify gene expression by changing the histone modifications and DNA methylation patterns without disturbing the fundamental DNA sequence. Genome editing has shown various therapeutic potentials with greater promises [26]. Satisfactory results have been found from the CRISPR-based therapies for sickle cell diseases and β-thalassemia in the clinical trials, and ongoing research is still going on for various targeted diseases, ranging from inherited retinal disorders to cancer and viral infections. Even after various

advancements, various technical barriers remain to clinical adoption, such as delivery mechanisms, off-target effects, unexpected immune responses, and ethical concerns in germline editing [26].

Altogether, the emergence of genome editing along with the tools has significantly redefined the pattern of studying genes and treating diseases. These tools have moved the research pattern from basic to advanced in clinical applications, specifically in arenas of altering disease-causing mutations. The continuous evolution of these studies, till today, is expected to treat a wider range of diseases with more precision and effectiveness.

VI. Artificial Intelligence and Computational Integration in Genomics

The rapid use of high-throughput sequencing, multi-omics profiling, and various imaging technologies has generated a large amount of complex biological data. Previously, analytical techniques often couldn't properly identify patterns, interactions, and functional interpretations at a large scale; later, to combat these challenges, artificial intelligence (AI) and machine learning (ML) emerged as an indispensable tool to decode the huge and complex datasets of modern genomics [27].

Different AI models like DeepSEA and ExPecto evolved for variant interpretation that improved the efficiency of predicting non-coding variant effects by integrating the context sequence and chromatin features [28,29]. In the field of transcriptomics and single-cell analysis, various unproven learning techniques like t-SNE, UMAP, along with novel generative models like scVI and scGen, permitted the clustering and various annotations of cell types, detection of rare populations, and modeling of cellular trajectories [30-32] .

AlphaFold2, a deep learning model developed by DeepMind, proved to be a breakthrough that accurately predicts 3D structures of proteins from amino acid sequences more efficiently than traditional approaches [33] . Its open-source release has created downstream applications in drug discovery and functional genomics, along with efficient analysis of structural biology. In recent times, Large language models (LLMs) such as ESMFold and ProGen are being trained to learn and analyze biologically meaningful data from various genomic, proteomic, and biochemical evaluations [34]. These models are now starting to predict various protein–protein interactions, computational protein designing, and even regulatory grammar in DNA sequences [35].

With the continuous evolution of AI and ML, their amalgamation with genomics is expected to deepen with the progress of time. Advancements in the future may include Explainable AI (XAI), multi-modal models, and more learning approaches that can learn with datasets worldwide without harming privacy.

VII. Multi-Omics Integration and Network Biology

A significant realization occurred when modern biology increasingly recognised the complex traits and diseases, but could not fully explain or understand them just by analysing a single layer of molecular information. This limitation gave rise to multi-omics integration, which is a coordinated analysis of diverse data types like genomics, transcriptomics, proteomics, metabolomics, and epigenomics that can provide a complete view of biological systems [36].

Multi-omics studies aim to disentangle the various dynamic regulatory interactions occurring throughout the cellular layers. Like, integrating transcriptomic data along with proteomic data helps to settle any differences between mRNA abundance and protein expression [37,38]. Similarly, combining epigenomic marks with chromatin accessibility and transcription factor binding can simplify the mechanisms of gene regulation. These types of integrative approaches have proved to be influential in outlining tumor subtypes, several neurological disorders, autoimmune diseases, and biomarkers in cancer and other complex conditions [39,40]. Network Biology provides a conceptual and computational framework for such combinations. Gene co-expression networks, protein-protein interaction (PPI) maps, and causal inference models help to identify gene hubs, pathway augmentations, and key reasons for phenotypic changes. Platforms like iClusterPlus, MOFA (Multi-Omics Factor Analysis), and DIABLO (Data Integration Analysis for Biomarker discovery) enable the reduction of dimensionality and selection of features across omic layers [41-43]. The development of The Cancer Genome Atlas (TCGA), the Human Proteome Project, and the International Human Epigenome Consortium (IHEC), which are cloud-based pipelines and data repositories, enabled researchers to access harmonised multi-omics datasets at ease from large regimens. These types of resources support system modelling at the system levels, along with the generation of predictive signatures for any disease risk, its progression, and therapeutic response [44,45].

In spite of having a lot of advantages, multi-omics integration faces various challenges. This includes technical variability across platforms, missing data, computational complexity of harmonizing datasets, and many more. Nonetheless, innovations in ML, statistical modelling, and standardization of pipelines are continuously addressing these hurdles, which together are moving the field towards real-time clinical utility.

VIII. Population-Scale Genomics and Biobanks

With the increase in the genomic revolution, the focus shifted from sequencing individuals to sequencing an entire population, along with the contributions of large-scale biobanks. These combined efforts aim to analyse genetic differences across varied ancestries, link genomic data with

Electronic Health Records (EHRs), and understand genotype-phenotype relationships that can inform about health risk, drug response, and precision medicine [46].

Various landmark projects like the UK Biobanks store phenotypic and genomic data from over 500,000 participants and have prepared the combination of genomic information with their lifestyle, environmental, and clinical records [47]. In the same way, the All of Us Research Program based in the USA emphasized recruiting participants from various historically marginalised groups, thus addressing ancestral-related biases in the genomic database [48]. The China Kadoorie Biobank and Taiwan Biobank in Asia have significantly contributed massive datasets to support area-specific disease risk prediction along with trans-ethnic meta-analyses. These area-specific population-scale resources have assisted in genome–wide association studies (GWAS) modelling, and analysis of rare variants at an exceptional scale and resolution [49,50]. Additionally, GWAS supports precise mapping of disease loci along with Mendelian randomisation analysis to understand causal pathways.

Despite having all these advancements, the challenges remain. In Most of the genomic datasets, proportional representation of African, Indigenous, and South Asian ancestries is still absent. This limits the universality of predicting polygenetic risks along with genetic findings [51]. Different initiatives like the African Genome Variation Project, GenomeAsia 100k, and H3Africa are working hard to overcome this challenge by closing this gap and promoting unbiased access to genomic medicine [52,53]. Significant ethical, legal, and social considerations arise from biobanks, including consent models, data privacy, commercialization, and community engagement. All these concerns demand continuous coordination among researchers, policy makers, and participant communities to build trust and to ensure responsible usage of data [54].

IX. Single-Cell and Spatial Genomics — Mapping Cellular Heterogeneity

While population genomics provides bulk-level averages, it potentially hides the diversity of cell states, types, and trajectories that are responsible for development, disease, and therapeutic responses. Single-cell genomics emerged in the early 2010s to overcome this limitation and thus offers exceptional resolution into individual cellular behaviour and identity [55].

Its foundational technique, i.e., single-cell RNA sequencing (scRNA-seq), enables transcriptome-wide profiling of millions and millions of individual cells. Revolutionary platforms like Drop-seq, SMART-seq, and 10x Genomics Chromium standardised these technologies by incorporating them with microfluidics, barcoding, and next-generation sequencing [56,57]. All these innovations fueled the formation of large-scale reference atlases, most significantly the Human Cell Atlas (HCA). The HCA aims to categorise each cell type present in the human body [58].

Transcriptomics has long been a cornerstone of single-cell biology, yet recent methodological advances—most notably single-cell ATAC-seq (chromatin accessibility), genome-wide methylome profiling, and multi-omics protocols such as CITE-seq and SHARE-seq—have opened new frontiers in the interrogation of gene regulation at the single-cell scale [59-61]. Such tools have helped clarify lineage hierarchies among stem cells, intratumoral heterogeneity in cancer, immune-cell dynamics during infection, and regenerative-medicine response trajectories. Spatial transcriptomics adds a stratum of resolution by preserving the anatomical context of gene expression within intact tissue. Technologies including Slide-seq, MERFISH, and 10x Visium now allow researchers to visualize where specific mRNAs are expressed within tissue architecture, thereby integrating histological insights with genomic precision [62,63]. A key comparison of major single-cell technologies, along with spatial transcriptomics, is illustrated in Table 1. From a computational standpoint, single-cell data demand sophisticated pipelines for dimensionality reduction, batch correction, and trajectory inference . Seurat, Scanpy, and Monocle have become established, but there are still issues, including dropout events, technical noise, scalability, and cross-platform harmonization. There is an increasing pace of clinical translation. Mechanisms of immune evasion and resistance to immunotherapies can be uncovered using single-cell methods in oncology. They have exposed the cellular diversity in the brain areas that were considered to be homogenous in neuroscience. Developmental biology. In developmental biology, single-cell data have been used to determine lineage histories and when cell fate decisions were made. In the future, the combination of multi-modality and in vivo perturbation technologies indicates the development of dynamic, 4-dimensional maps of living systems to single-cell resolution, thereby bridging the gap between genotype to phenotype in real time [64].

Year	Technology	Principle	Application
2012	SMART-Seq	Amplification of full-length cDNA from single cells	Highly sensitive, covers full transcript
2015	Drop-Seq	Cell barcoding of microfluidic droplets	Scalable for large number of cells, cost effective
2016	10x Chromium	Gel bead-in-emulsion(GEM) droplet partitioning	Commercially viable, high throughput
2015	MERFISH	Multiplexed error-robust in situ hybridization	High gene multiplexing with spatial resolution
2019	Visium (10x)	Spatially barcoded capture spots on slides	Combination of transcriptomica and histology
2015	scATAC-Seq	Single-cell level transposase-accessible chromatin profiling	Opens chromatin regions genome-wide

Table 1: Major single-cell genomics and spatial transcriptomics technologies from 2000 to 2025

X. Ethical, Legal, and Social Implications (ELSI)

As the genetic and genomic technologies are rising day by day, it has been very difficult to ignore their ethical, legal, and social dimensions. Over the last 25 years, discussions have been going on centered on issues like informed consent, data privacy, data ownership, genetic discrimination, and the limitations of genome editing [65].

Germline editing is considered one of the most contentious topics. While treatments only targeting patients' cells are globally accepted, any modification that can be passed on to future generations raises serious questions related to autonomy, consent, and the risk of eugenics. CRISPR-edited babies in China, a case in 2018, brought these concerns into serious consideration. As a consequence, organizations like the WHO and the National Academies of Science, Engineering, and Medicine called for firm, globally accepted rules, clear oversight, and public engagement [66,67].

Biobanks possess serious concerns, too. A huge accumulation of genetic data from the whole population can lead a further research, but at the same time also raises questions about the need for consent over time, the data sharing process, and how samples might be used in the future. Various biobanks have now opted for tiered or renewable consent models along with federated data systems, which allow research on global subjects while maintaining their privacy [68,69].

The integration of AI is also raising serious ethical concerns. Various tools for genomic predictions are being made based on the data that are heavily overrepresented by people of European ancestry. This leads to errors, injustices, and lower access to precision medicine for underserved people [70].

Direct-to-consumer testing of genes is another set of issues. While it offers simple access to personal genetic information, the accuracy of results, availability of proper genetic counselling, and psychological impact on the consumer are still very questionable. Regulatory bodies such as the FDA and EMA are still reframing their approach to equilibrate innovations with consumer protection [71].

Cultural and political perspectives are also included in the ELSI debate. Indigenous communities are more involved in genomic research, thus taking stronger control, which poses a threat to data sovereignty and equal benefit sharing. Programs like CARE (Collective Benefit, Authority to Control, Responsibility, and Ethics) ensure that progress in such research must be done in ways that respect different community values [72].

XI. Emerging Frontiers and Future Directions

As we move into the next phase of the genomic century, we intend to reshape our understanding of life. The future is about exploring and inventing various real-time inventions, which are less about speculation and more about the meaningful development of tools, applications, and collaborations.

Long-read sequencing technologies, specifically from Oxford Nanopore and PacBio, are now able to resolve various structural complexities of the human genome that were once thought to be impossible. These platforms enable complete, telomere-to-telomere assemblies, recognise full-length transcripts, and expose epigenetic signatures at a single-molecule level. In our view, these different tools mark a shift from sequencing each fragment to sequencing functions, where the role of DNA is evaluated [73,74].

Single-cell and spatial multi-omics are no longer isolated, but rather, they are adding up to provide living graphics of cellular behaviour. Many projects like Human Cell Atlas and Tumor Atlas Network generate a 4D mapping system to capture cellular architecture, their functions, and fate decisions over the period. Clinical genomics, which was once limited to rare disease diagnostics, is now venturing into polygenic risk scoring, liquid biopsies for early cancer detection, and pharmacogenomics [75,76]. The amalgamation of genomics into electronic health records (EHRs) and other digital platforms. This brings us closer to the concept of P4 medicine- predictive, preventive, personalized, and participatory [77].

Artificial intelligence (AI), specifically large foundation models trained on multimodal biological data, is expected to fast-track the drug discovery process, protein design, variant effect prediction, and gene regulatory modeling. Different foundational models like AlphaFold-Multimer, ESM-Atlas, and LLMs are generating this new biological insight [78].

On the global level, large-scale consortia are gaining equity and accessibility. The GenomeAsia 100K, Earth BioGenome Project, and telomere-to-telomere programmes are generating more representative genomes as references. Meanwhile, various policies surrounding open science, the Ethical use of AI, and data dominance are becoming integral pillars for an impartial genomics ecosystem [79,80].

These developments are not hypothetical; rather, they are already transforming the laboratory practices, clinical pipelines, and public policies. The advancing years are expected not to focus solely on generating huge volumes of data, but to achieve meaningful integration of genomics into broader fields of medicine, biology, and healthcare. The next era is likely to be characterized by the integration of technological advancements, ethical considerations, and international collaborations,

which will ensure the continued evolution of genomic science as both a driver of discovery and a pillar of societal benefits.

XII. Conclusion

Over the last 25 years, the field of genomics has progressed from a data-limited process to a core driver of modern-day biology and medicine. Innovations in long-read sequencing, single-cell multi-omics, AI-enabled analytics, and transcriptomics allowed characterization of living systems at a single-cell level, which reveals heterogeneity that mass approaches cannot capture. The extension of large-scale biobanks and globally accessible data platforms, along with ethical considerations, has accelerated the amalgamation of genomics into precision healthcare.

Despite impressive progress in human genomics, several obstacles persist. Inequities in the population representation, heterogeneity in the data quality, bias in the algorithms, and the technical hindrance and conversion of technical data into medically actionable is a major hurdles. Ongoing innovation in genomics will necessitate the concurrent advancement of technologies that are both reproducible and interpretable, alongside the equitable provision of access. These gaps can only be filled through interdisciplinary cooperation between molecular biology, computational science, clinical research, and policy.

The next horizon for genomics research should center on tools and frameworks that are simultaneously high-performing and globally applicable, emphasizing context-aware analyses that weave genetic, environmental, and developmental dimensions together. By prioritizing actionable insights over data generation alone, genomics can continue to evolve as a transformative discipline, shaping healthcare, research, and policy across diverse populations worldwide.

References

[1] Collins FS. Genome research: The next generation. Cold Spring Harb Symp Quant Biol. 2003;68:49-54. https://doi.org/10.1101/sqb.2003.68.49

[2] Waterston RH, Lander ES, Sulston JE. On the sequencing of the human genome. Proc Natl Acad Sci U S A. 2002;99(6):3712-6. https://doi.org/10.1073/pnas.042692499

[3] Mardis ER. The impact of next-generation sequencing technology on genetics. Trends Genet. 2008;24(3):133-41. https://doi.org/10.1016/j.tig.2007.12.007

[4] Shendure J, Balasubramanian S, Church GM, Gilbert W, Rogers J, Schloss JA, et al. DNA sequencing at 40: past, present and future. Nature. 2017;550(7676):345-53. https://doi.org/10.1038/nature24286

[5] Doudna JA, Charpentier E. The new frontier of genome engineering with CRISPR-Cas9. Science. 2014;346(6213):1258096. https://doi.org/10.1126/science.1258096

[6] Ching T, Himmelstein DS, Beaulieu-Jones BK, Kalinin AA, Do BT, Way GP, et al. Opportunities and obstacles for deep learning in biology and medicine. J R Soc Interface. 2018;15(141):20170387.

[7] Conley JM, Davis AM, Henderson GE, Juengst ET, Meagher KM, Walker RL, et al. A new governance approach to regulating human genome editing. N C J Law Technol. 2020;22(2):107-64.

[8] Shozi B, Kamwendo T, Kinderlerer J, Thaldar DW, Townsend B, Botes M. Future of global regulation of human genome editing: a South African perspective on the WHO Draft Governance Framework on Human Genome Editing. J Med Ethics. 2022;48(3):165-8.

[9] Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, et al. Initial sequencing and analysis of the human genome. Nature. 2001;409:860-921.

[10] Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, Sutton GG, et al. The sequence of the human genome. Science. 2001;291(5507):1304-51.

[11] ENCODE Project Consortium. An integrated encyclopedia of DNA elements in the human genome. Nature. 2012;489(7414):57-74. https://doi.org/10.1038/nature11247

[12] 1000 Genomes Project Consortium. A global reference for human genetic variation. Nature. 2015;526(7571):68-74. https://doi.org/10.1038/nature15393

[13] Yates AD, Achuthan P, Akanni W, Allen J, Alvarez-Jarreta J, Amode MR, et al. Ensembl 2020. Nucleic Acids Res. 2020;48(D1):D682-8. https://doi.org/10.1093/nar/gkz966

[14] Ansorge WJ, Katsila T, Patrinos GP. Perspectives for future DNA sequencing techniques and applications. InMolecular Diagnostics 2017 Jan 1 (pp. 141-153). Academic Press.

[15] Mardis ER. Next-generation DNA sequencing methods. Annu Rev Genomics Hum Genet. 2008;9:387-402. https://doi.org/10.1146/annurev.genom.9.081307.164359

[16] Ashley EA. Towards precision medicine. Nat Rev Genet. 2016;17(9):507-22. https://doi.org/10.1038/nrg.2016.86

[17] Wenger AM, Peluso P, Rowell WJ, Chang PC, Hall RJ, Concepcion GT, et al. Accurate circular consensus long-read sequencing improves variant detection and assembly of a human genome. Nat Biotechnol. 2019;37(10):1155-62. https://doi.org/10.1038/s41587-019-0217-9

[18] Kim YG, Cha J, Chandrasegaran S. Hybrid restriction enzymes: zinc finger fusions to Fok I cleavage domain. Proc Natl Acad Sci U S A. 1996;93(3):1156-60. https://doi.org/10.1073/pnas.93.3.1156

[19] Christian M, Cermak T, Doyle EL, Schmidt C, Zhang F, Hummel A, et al. Targeting DNA double-strand breaks with TAL effector nucleases. Genetics. 2010;186(2):757-61. https://doi.org/10.1534/genetics.110.120717

[20] Doudna JA, Charpentier E. The new frontier of genome engineering with CRISPR-Cas9. Science. 2014;346(6213):1258096. https://doi.org/10.1126/science.1258096

[21] Komor AC, Kim YB, Packer MS, Zuris JA, Liu DR. Programmable base editing without DNA cleavage. Nature. 2016;533(7603):420-4. https://doi.org/10.1038/nature17946

[22] Anzalone AV, Randolph PB, Davis JR, Sousa AA, Koblan LW, Levy JM, et al. Search-and-replace genome editing without double-strand breaks. Nature. 2019;576(7785):149-57. https://doi.org/10.1038/s41586-019-1711-4

[23] Liu XS, Wu H, Ji X, Stelzer Y, Wu X, Czauderna S, et al. Editing DNA methylation in the mammalian genome. Cell. 2016;167(1):233-47. https://doi.org/10.1016/j.cell.2016.08.056

[24] Hilton IB, D'Ippolito AM, Vockley CM, Thakore PI, Crawford GE, Reddy TE, et al. Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates gene expression. Nat Biotechnol. 2015;33(5):510-7. https://doi.org/10.1038/nbt.3199

[25] Frangoul H, Altshuler D, Cappellini MD, Chen YS, Domm J, Eustace BK, et al. CRISPR-Cas9 gene editing for sickle cell disease and β-thalassemia. N Engl J Med. 2021;384(3):252-60.

[26] Cox DBT, Platt RJ, Zhang F. Therapeutic genome editing: prospects and challenges. Nat Med. 2015;21(2):121-31.

[27] Christensen BC, Gitter A, Himmelstein DS, Titus AJ, Levy JJ, Greene CS, Elton DC. Opportunities and obstacles for deep learning in biology and medicine [update in progress]. Manubot; 2021 Dec 28.

[28] Zhou J, Troyanskaya OG. Predicting effects of noncoding variants with deep learning–based sequence model. Nat Methods. 2015;12(10):931-4.

[29] Zhou J, Theesfeld CL, Yao K, Chen KM, Wong AK, Troyanskava OG. Deep learning sequence-based ab initio prediction of variant effects on expression and disease risk. Nat Genet. 2018;50(8):1171-9.

[30] Becht E, McInnes L, Healy J, Dutertre CA, Kwok IW, Ng LG, et al. Dimensionality reduction for visualizing single-cell data using UMAP. Nat Biotechnol. 2019;37(1):38-44.

[31] Lopez R, Regier J, Cole MB, Jordan MI, Yosef N. Deep generative modeling for single-cell transcriptomics. Nat Methods. 2018;15(12):1053-8.

[32] Lotfollahi M, Wolf FA, Theis FJ. scGen predicts single-cell perturbation responses. Nat Methods. 2019;16(8):715-21.

[33] Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, et al. Highly accurate protein structure prediction with AlphaFold. Nature. 2021;596(7873):583-9.

[34] Rives A, Meier J, Sercu T, Goyal S, Lin Z, Liu J, et al. Biological structure and function emerge from scaling unsupervised learning to 250 million protein sequences. Proc Natl Acad Sci U S A. 2021;118(15):e2016239118.

[35] Obermeyer Z, Powers B, Vogeli C, Mullainathan S. Dissecting racial bias in an algorithm used to manage the health of populations. Science. 2019;366(6464):447-53.

[36] Hasin Y, Seldin M, Lusis A. Multi-omics approaches to disease. Genome Biol. 2017;18(1):83. https://doi.org/10.1186/s13059-017-1215-1

[37] Subramanian I et al. Multi-omics data integration, interpretation, and its application. Bioinform Biol Insights. 2020;14:1177932219899051. https://doi.org/10.1177/1177932219899051

[38] Civelek M, Lusis AJ. Systems genetics approaches to understand complex traits. Nat Rev Genet. 2014;15(1):34-48. https://doi.org/10.1038/nrg3575

[39] Zhu Y et al. Integrating multi-omics for uncovering the architecture of cross-talking pathways in breast cancer. Front Genet. 2019;10:470.

[40] Kogelman LJA et al. Integration of multi-omics data to identify key molecular drivers in a pig model for metabolic syndrome. BMC Genomics. 2018;19:709.

[41] Shen R et al. Integrative clustering of multiple genomic data types using iCluster. Bioinformatics. 2009;25(22):2906-12. https://doi.org/10.1093/bioinformatics/btp543

[42] Argelaguet R et al. Multi-Omics Factor Analysis—a framework for unsupervised integration of multi-omics data sets. Mol Syst Biol. 2018;14(6):e8124. https://doi.org/10.15252/msb.20178124

[43] Singh A et al. DIABLO: an integrative approach for identifying key molecular drivers from multi-omics assays. Bioinformatics. 2019;35(17):3055-62. https://doi.org/10.1093/bioinformatics/bty1054

[44] Tomczak K, Czerwińska P, Wiznerowicz M. The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge. Contemp Oncol (Pozn). 2015;19(1A):A68-77. https://doi.org/10.5114/wo.2014.47136

[45] Bujold D et al. The International Human Epigenome Consortium Data Portal. Cell Syst. 2016;3(5):496-9. https://doi.org/10.1016/j.cels.2016.10.019

[46] Manolio TA, Fowler DM, Starita LM, Haendel MA, MacArthur DG, Biesecker LG, et al. Bedside back to bench: building bridges between basic and clinical genomic research. Cell. 2017;169(1):6–12. https://doi.org/10.1016/j.cell.2017.03.005

[47] Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, et al. The UK Biobank resource with deep phenotyping and genomic data. Nature. 2018;562(7726):203–9. https://doi.org/10.1038/s41586-018-0579-z

[48] Denny JC, Rutter JL, Goldstein DB, Philippakis A, Smoller JW, Jenkins G, et al. The "All of Us" Research Program. N Engl J Med. 2019;381(7):668–76. https://doi.org/10.1056/NEJMsr1809937

[49] Chen Z, Chen J, Collins R, Guo Y, Peto R, Wu F, et al. China Kadoorie Biobank of 0.5 million people: survey methods, baseline characteristics and long-term follow-up. Int J Epidemiol. 2011;40(6):1652–66. https://doi.org/10.1093/ije/dyr120

[50] Chen CH, Chen YT, Chen HS, Lai TY, Lee TY, Liu DJ, et al. Taiwan Biobank: a project aiming to aid Taiwan's transition into precision medicine. NPJ Genomic Med. 2016;1:16022. https://doi.org/10.1038/npjgenmed.2016.22

[51] Sirugo G, Williams SM, Tishkoff SA. The missing diversity in human genetic studies. Cell. 2019;177(1):26–31. https://doi.org/10.1016/j.cell.2019.02.048

[52] Bentley AR, Callier S, Rotimi CN. The African Genome Variation Project shapes medical genetics in Africa. Nature. 2017;517(7534):327–32. https://doi.org/10.1038/nature13997

[53] Gurdasani D, Barroso I, Zeggini E, Sandhu MS. Genomics of disease risk in globally diverse populations. Nat Rev Genet. 2019;20(9):520–35. https://doi.org/10.1038/s41576-019-0155-6

[54] Thorogood A, Hoeyer K, Schicktanz S. Dynamic consent: a possible solution to improve participant engagement in biobank research. Eur J Hum Genet. 2021;29(1):6–9. https://doi.org/10.1038/s41431-020-00714-0

[55] Tang F, Barbacioru C, Wang Y, Nordman E, Lee C, Xu N, et al. mRNA-Seq whole-transcriptome analysis of a single cell. Nat Methods. 2009;6(5):377–82. https://doi.org/10.1038/nmeth.1315

[56] Macosko EZ, Basu A, Satija R, Nemesh J, Shekhar K, Goldman M, et al. Highly parallel genome-wide expression profiling of individual cells using nanoliter droplets. Cell. 2015;161(5):1202–14. https://doi.org/10.1016/j.cell.2015.05.002

[57] Zheng GX, Terry JM, Belgrader P, Ryvkin P, Bent ZW, Wilson R, et al. Massively parallel digital transcriptional profiling of single cells. Nat Commun. 2017;8:14049. https://doi.org/10.1038/ncomms14049

[58] Regev A, Teichmann SA, Lander ES, Amit I, Benoist C, Birney E, et al. The Human Cell Atlas. eLife. 2017;6:e27041. https://doi.org/10.7554/eLife.27041

[59] Buenrostro JD, Wu B, Chang HY, Greenleaf WJ. Single-cell chromatin accessibility reveals principles of regulatory variation. Nature. 2015;523(7561):486–90. https://doi.org/10.1038/nature14590

[60] Stoeckius M, Hafemeister C, Stephenson W, Houck-Loomis B, Chattopadhyay PK, Swerdlow H, et al. Simultaneous epitope and transcriptome measurement in single cells. Nat Methods. 2017;14(9):865–8. https://doi.org/10.1038/nmeth.4380

[61] Ma S, Zhang B, LaFave LM, Earl AS, Chiang Z, Hu Y, et al. Chromatin potential identified by shared single-cell profiling of RNA and chromatin. Cell. 2020;183(4):1103–16.e20. https://doi.org/10.1016/j.cell.2020.10.024

[62] Rodriques SG, Stickels RR, Goeva A, Martin CA, Murray E, Vanderburg CR, et al. Slide-seq: a scalable technology for measuring genome-wide expression at high spatial resolution. Science. 2019;363(6434):1463–7. https://doi.org/10.1126/science.aaw1219

[63] Xia C, Fan J, Emanuel G, Hao J, Zhuang X. MERFISH enables spatially resolved, highly multiplexed RNA profiling in single cells. Cell. 2019;178(2):429–44.e16. https://doi.org/10.1016/j.cell.2019.06.022

[64] Satija R, Farrell JA, Gennert D, Schier AF, Regev A. Spatial reconstruction of single-cell gene expression data. Nat Biotechnol. 2015;33(5):495–502. https://doi.org/10.1038/nbt.3192

[65] Tutton R, Prainsack B, Zimmern R, et al. Genomics and society: ethical implications of genetic information. Annu Rev Genomics Hum Genet. 2021;22:495–517. https://doi.org/10.1146/annurev-genom-091020-111419

[66] National Academies of Sciences, Engineering, and Medicine. Heritable Human Genome Editing. Washington, DC: The National Academies Press; 2020. https://doi.org/10.17226/25665

[67] WHO Expert Advisory Committee. Human Genome Editing: Recommendations. Geneva: World Health Organization; 2021.

[68] Kaye J, Whitley EA, Lund D, Morrison M, Teare H, Melham K. Dynamic consent: a patient interface for twenty-first century research networks. Eur J Hum Genet. 2015;23(2):141–146. https://doi.org/10.1038/ejhg.2014.123

[69] Knoppers BM. Framework for responsible sharing of genomic and health-related data. Hum Genet. 2014;133(7):895–903. https://doi.org/10.1007/s00439-014-1478-2

[70] Obermeyer Z, Powers B, Vogeli C, Mullainathan S. Dissecting racial bias in an algorithm used to manage the health of populations. Science. 2019;366(6464):447–453. https://doi.org/10.1126/science.aax2342

[71] Phillips AM. Only a click away—DTC genetics for ancestry, health, love…and more. N Engl J Med. 2018;378(11):1023–1031. https://doi.org/10.1056/NEJMms1707601

[72] Carroll SR, Garba I, Figueroa-Rodríguez OG, et al. The CARE principles for Indigenous data governance. Data Sci J. 2020;19(1):43. https://doi.org/10.5334/dsj-2020-043

[73] Miga KH, Koren S, Rhie A, Vollger MR, Gershman A, Bzikadze A, et al. Telomere-to-telomere assembly of a complete human X chromosome. Nature. 2020;585(7823):79–84. https://doi.org/10.1038/s41586-020-2547-7

[74] Logsdon GA, Vollger MR, Hsieh P, Mao Y, Liskovykh MA, Koren S, et al. The structure, function and evolution of a complete human chromosome 8. Nature. 2021;593(7857):101–107. https://doi.org/10.1038/s41586-021-03420-7

[75] Regev A, Teichmann SA, Lander ES, Amit I, Benoist C, Birney E, et al. The Human Cell Atlas. eLife. 2017;6:e27041. https://doi.org/10.7554/eLife.27041

[76] Lin Y, Lan X, Jansen C, Chen C, Majumder P, Stojanovic A, et al. Spatial transcriptomics: technologies and applications. J Hematol Oncol. 2021;14(1):129. https://doi.org/10.1186/s13045-021-01176-1

[77] Ashley EA. The precision medicine initiative: a new national effort. JAMA. 2016;315(7):713–714. https://doi.org/10.1001/jama.2015.18641

[78] Rives A, Meier J, Sercu T, Goyal S, Lin Z, Liu J, et al. Biological structure and function emerge from scaling unsupervised learning to 250 million protein sequences. Proc Natl Acad Sci U S A. 2021;118(15):e2016239118. https://doi.org/10.1073/pnas.2016239118

[79] Lewin HA, Robinson GE, Kress WJ, Baker WJ, Coddington J, Crandall KA, et al. Earth BioGenome Project: Sequencing life for the future of life. Proc Natl Acad Sci U S A. 2018;115(17):4325–4333. https://doi.org/10.1073/pnas.1720115115

[80] Fatumo S, Chikowore T, Choudhury A, Ayub Q, Aminkeng F, Whitlock K, et al. A roadmap to increase diversity in genomic studies. Nat Med. 2022;28(2):243–250. https://doi.org/10.1038/s41591-021-01672-4